{"nctId":"NCT02319005","briefTitle":"ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)","startDateStruct":{"date":"2014-12"},"conditions":["Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)","Amyloidosis, Hereditary","Amyloid Neuropathies, Familial","Amyloid Neuropathies","Amyloidosis, Hereditary, Transthyretin-Related","Familial Transthyretin Cardiac Amyloidosis"],"count":206,"armGroups":[{"label":"Revusiran (ALN-TTRSC)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Revusiran (ALN-TTRSC)"]},{"label":"Sterile Normal Saline (0.9% NaCl)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Sterile Normal Saline (0.9% NaCl)"]}],"interventions":[{"name":"Revusiran (ALN-TTRSC)","otherNames":[]},{"name":"Sterile Normal Saline (0.9% NaCl)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented TTR mutation\n* Amyloid deposits in cardiac or non-cardiac tissue\n* Medical history of heart failure\n* Evidence of cardiac involvement by echocardiogram\n\nExclusion Criteria:\n\n* Has known primary amyloidosis (AL), leptomeningeal amyloidosis, non-FAC hereditary cardiomyopathy, hypertensive cardiomyopathy, or cardiomyopathy due to valvular heart disease\n* Has known peripheral vascular disease affecting ambulation\n* Has a Polyneuropathy Disability score \\>2\n* Has a New York Heart Association (NYHA) classification of IV","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"6 Minute Walk Distance (6-MWD)","description":"The difference between revusiran and placebo group in change from baseline to 18 months in the total distance walked in 6 minutes","classes":[]},{"type":"PRIMARY","title":"Serum TTR Levels","description":"The difference between revusiran (ALN-TTRSC) and placebo group in the percent reduction in serum TTR levels over 18 months","classes":[]},{"type":"SECONDARY","title":"Composite Cardiovascular (CV) Mortality and Cardiovascular (CV) Hospitalization","description":"Number of cardiovascular-related deaths and cardiovascular-related hospitalizations in the placebo group compared to the revusiran (ALN-TTRSC) treatment group","classes":[]},{"type":"SECONDARY","title":"New York Heart Association (NYHA) Class","description":"The difference between revusiran (ALN-TTRSC) and placebo group in the change from baseline to 18 months in the NYHA class","classes":[]},{"type":"SECONDARY","title":"Kansas City Cardiomyopathy Questionnaire (KCCQ)","description":"The difference between revusiran (ALN-TTRSC) and placebo group in the change from Baseline to 18 months in the Kansas City Cardiomyopathy Questionnaire","classes":[]},{"type":"SECONDARY","title":"Cardiovascular (CV) Mortality","description":"Number of cardiovascular-related deaths in the placebo group compared to the revusiran (ALN-TTRSC) treatment group","classes":[]},{"type":"SECONDARY","title":"Cardiovascular (CV) Hospitalization","description":"Number of cardiovascular-related hospitalizations in the placebo group compared to the revusiran (ALN-TTRSC) treatment group","classes":[]},{"type":"SECONDARY","title":"All-cause Mortality","description":"Total number of deaths in the placebo group compared to the revusiran (ALN-TTRSC) treatment group","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":83,"n":140},"commonTop":["Cough","Constipation","Dizziness","Injection Site Pain","Neuropathy peripheral"]}}}